Sonidegib

• Description:

  Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively[1].

• Product Name Alternative:

  Erismodegib; LDE225; NVP-LDE225

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Smo

• Type:

  Reference compound

• Related Pathways:

  Stem Cell/Wnt

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/lde225.html

• Purity:

  99.94

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=C(C)C(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)NC3=CC=C(N=C3)N4C[C@@H](C)O[C@@H](C)C4

• Molecular Formula:

  C26H26F3N3O3

• Molecular Weight:

  485.50

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Pan S, et al. Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. ACS Med Chem Lett. 2010 Mar 16;1 (3) :130-4.|[2]Irvine DA, et al. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Sci Rep. 2016 May 9;6:25476.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  BioRxiv. 2023 Nov 6:2023.11.03.565570.|bioRxiv. 2024 Jul 25.|bioRxiv. 2024 Nov 4:2024.10.08.617155.|bioRxiv. 2025 Oct 11.|Cell Physiol Biochem. 2018;47 (4) :1352-1364.|J Pathol. 2025 Nov 6.|SSRN. 2025 Jul 25.|Tissue Cell. 2024 Nov 28:92:102643.|J Genet Genomics. 2018 May 20;45 (5) :237-246.|Nat Med. 2018 Nov;24 (11) :1752-1761. |Patent. US20180263995A1.

• CAS Number:

  [956697-53-3]